Arbutus Announces Closing of the Second Tranche of a $116M Strategic Investment from Roivant Sciences

Stock Information for Arbutus Biopharma Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Arbutus Biopharma Corporation

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
Arbutus to Participate in Two Upcoming Investor Conferences
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.